
Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: A retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy
Keywords: استروژن; BCL2; TP53; Biomarkers; Breast cancer; Expression; Prognosis; BC; breast cancer; BCL2; B-cell leucemia/lymphoma 2; CMF; cyclophosphamide, methotrexate, fluorouracil regimen; EC; epirubicin, cyclophosphamide regimen; EFS; event free survival; ER; estrogen